IL4R;IL4RA;582J2.1

Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)]

Homo sapiens (Human)

89658

825

N/A

Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)]

N/A

MUTAGEN 38 38 Y->A: 700-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 38 38 Y->F: 25-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 39 39 M->A: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 40 40 S->A: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 64 64 L->A: 100-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 66 66 F->A: 45-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 67 67 L->A: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 68 68 L->A: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 91 91 D->A: Little effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 92 92 D->A: 50-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 93 93 V->A: Little effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 94 94 V->A: 35-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 95 95 S->A: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 97 97 D->A,N: >150-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 98 98 N->A: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 99 99 Y->A: 10-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 116 116 K->A: Little effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 117 117 P->A: Little effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 118 118 S->A: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 119 119 E->A: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 150 150 D->A: Little effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 151 151 N->A: Little effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 152 152 Y->A: 40-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 152 152 Y->F: No effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 153 153 L->A: Little effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 154 154 Y->A: Little effect on IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 208 208 Y->A: 500-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 208 208 Y->F: 200-fold reduction in IL4 binding. {ECO:0000269|PubMed:11786020}.; MUTAGEN 497 497 Y->F: Abolishes IRS1 tyrosine phosphorylation. No cell proliferation. {ECO:0000269|PubMed:8124718}.; MUTAGEN 575 575 Y->F: Loss of CD23 gene induction; when associated with F-603 and F-631. {ECO:0000269|PubMed:10201973, ECO:0000269|PubMed:8624803}.; MUTAGEN 603 603 Y->F: Loss of CD23 gene induction; when associated with F-575 and F-631. {ECO:0000269|PubMed:8624803}.; MUTAGEN 631 631 Y->F: Loss of CD23 gene induction; when associated with F-575 and F-603. {ECO:0000269|PubMed:8624803}.; MUTAGEN 713 713 Y->F: Increased IL4-induced cell proliferation and STAT6 activation. {ECO:0000269|PubMed:11714803}.

MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRAWAQCYNTTWSEWSPSTKWHNSYREPFEQHLLLGVSVSCIVILAVCLLCYVSITKIKKEWWDQIPNPARSRLVAIIIQDAQGSQWEKRSRGQEPAKCPHWKNCLTKLLPCFLEHNMKRDEDPHKAAKEMPFQGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVECEEEEEVEEEKGSFCASPESSRDDFQEGREGIVARLTESLFLDLLGEENGGFCQQDMGESCLLPPSGSTSAHMPWDEFPSAGPKEAPPWGKEQPLHLEPSPPASPTQSPDNLTCTETPLVIAGNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVEPEMPCVPQLSEPTTVPQPEPETWEQILRRNVLQHGAAAAPVSAPTSGYQEFVHAVEQGGTQASAVVGLGPPGEAGYKAFSSLLASSAVSPEKCGFGASSGEEGYKPFQDLIPGCPGDPAPVPVPLFTFGLDREPPRSPQSSHLPSSSPEHLGLEPGEKVEDMPKPPLPQEQATDPLVDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGCCCGDRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSFHPAPGNAQSSSQTPKIVNFVSVGPTYMRVS

Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2. {ECO:0000269|PubMed:8124718}.; Soluble IL4R (sIL4R) inhibits IL4-mediated cell proliferation and IL5 up-regulation by T-cells. {ECO:0000269|PubMed:8124718}.

Alternative sequence (3); Beta strand (16); Chain (2); Compositional bias (3); Disulfide bond (2); Domain (1); Glycosylation (6); Helix (6); Modified residue (4); Motif (3); Mutagenesis (33); Natural variant (15); Region (2); Signal peptide (1); Site (8); Topological domain (2); Transmembrane (1); Turn (1); Isoform 1 and isoform 2 are highly expressed in activated T-cells.

Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)]

Recombinant

HEK293

Lyophilized

7.4-7.5

Sterile-filtered colorless solution

1mg/ml

Standard

PBS

SDS-PAGE

> 98%

RP-HPLC

-20°C

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.